Biotech · Private company
A2 Biotherapeutics Inc.
Track this companyFree. Adds A2 Biotherapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials55 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- A2B395Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- A2B530Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- A2B543Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- A2B694Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- xT CDx with HLA-LOH AssayPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- xT-Onco with HLA-LOH AssayPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- ApheresisSolid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Long Range NGS HLA typingSolid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Next Generation Sequencing (NGS)Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- No additional intervention administered in this long term follow-up studySolid Tumor CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) ProductsENROLLING_BY_INVITATION · started Jul 31, 2025ClinicalTrials.gov NCT06885424 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionPHASE1_PHASE2 · RECRUITING · started May 22, 2025ClinicalTrials.gov NCT06682793 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionPHASE1_PHASE2 · RECRUITING · started Apr 3, 2024ClinicalTrials.gov NCT06051695 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 28, 2023ClinicalTrials.gov NCT05736731 · fetched Nov 12, 2026
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRECRUITING · started Oct 29, 2021ClinicalTrials.gov NCT04981119 · fetched Nov 12, 2026